Patent Application
20100159464
This invention relates to methods for detecting DNA methyltransferase RNA (DNMT RNA) in bodily fluids such as blood, blood plasma and serum as a means for selecting patients for DNA methyltransferase-directed treatment approaches.
DNA methylation appears to play an important role in the pathogenesis and maintenance of cancer. Hypermethylation of tumor-associated genes such as tumor suppressor genes, and hypomethylation of other genomic DNA, are frequently observed in cancer. DNA methylation is to a large extent regulated by DNA methyltransferases, of which three DNA methyltransferase gene families are DNA methyltransferase 1 (DNMT1), DNA methyltransferase 2 (DNMT2), and DNA methyltransferase 3 (DNMT3). DNMT is thus expressed in many malignant and premalignant tissues, wherein in particular DNMT1 and DNA methyltransferase 3a (DNMT3a) and DNA methyltransferase 3b (DNMT3b), and particularly DNMT3b, is over-expressed in malignancy. Since ribonucleic acid (RNA) is essential for producing DNMT protein, detection and monitoring of DNA methyltransferase RNA (DNMT RNA) provides a method for assessing and monitoring DNMT gene expression, thereby providing a method for monitoring and determining the presence and propensity for aberrant DNA methylation. Such assessment of DNA methyltransferase gene expression further identifies patients who might benefit from DNA methyltransferase RNA-directed therapies, including antisense RNA therapies and micro-RNA (miRNA)-based therapies. DNMT RNA is associated with cancer and premalignancy, and is therefore characterized as a tumor-associated RNA herein.
As used herein, DNMT RNA indicates any DNA methyltransferase species, including but not limited to DNMT1, DNMT2, DNMT3, DNMT3a, DNMT3b, and any single nucleotide polymorphism (SNP) RNA variation associated thereof, and further, sequence identifiable portions thereof
Co-owned U.S. Pat. No. 6,329,179, incorporated herein by reference in its entirety, provides a method for detecting tumor-associated RNA in bodily fluids such as blood plasma and serum, wherein said RNA detection is used for detecting, monitoring, or evaluating cancer or premalignant conditions.
DNMT RNA being recognized herein as being tumor-associated RNA, there is a newly-appreciated need in the art to identify premalignant or malignant states in an animal, most preferably a human, by detecting in a qualitative or quantitative fashion DNMT RNA such as DNMT1 RNA, DNMT3a RNA, and DNMT3b RNA in bodily fluids such as blood, blood plasma or serum. Further, there is a need in the art to evaluate the predisposition in an animal, most preferably a human, for diseases characterized by aberrant DNA methylation, including DNA hypermethylation and hypomethylation, by detecting DNMT RNA in bodily fluids such as blood plasma or serum, wherein cancer is one such disease, and whereby patients who might benefit from DNA methyltransferase RNA-directed therapies can be identified.
The present invention describes a method of evaluating an animal, most preferably a human, for premalignant or malignant states, disorders or conditions by detecting DNMT mRNA in bodily fluids, preferably blood and most preferably blood fractions such as circulating cells, plasma and serum, as well as in other bodily fluids, preferably urine, effusions, ascites, saliva, cerebrospinal fluid, cervical, vaginal, and endometrial secretions, gastrointestinal secretions, bronchial secretions, and associated tissue washings and lavages. Specific DNMT RNA are recognized to include DNMT1 RNA, DNMT2 RNA, DNMT3a RNA, and DNMT3b RNA. Detection of DNMT mRNA in said bodily fluids and fractions thereof allows determination of DNMT mRNA overexpression, and thereby enables identification and selection of humans or animals for therapies, preferably cancer therapies, directed at a DNMT mRNA target. Therapeutic approaches that target DNMT mRNA include antisense mRNA directed against DNMT mRNA, and microRNA (miRNA) or other inhibitory RNA (siRNA) therapeutic approaches including synthetic miRNA or siRNA that are directed against DNMT mRNA targets, such as against DNMT3b RNA, and further include drugs that inhibit DNMT DNA function or DNMT protein function. The identification of humans who overexpress DNMT mRNA such as DNMT3b mRNA is beneficial by allowing the selection of said humans for appropriate therapies while avoiding therapies and associated toxicities to individuals unlikely to benefit from them.
The invention provides the method of amplifying and detecting extracellular DNMT RNA. In a preferred embodiment, the present invention provides a method for detecting DNMT RNA in blood or a blood fraction, including plasma and serum, or in other bodily fluids, the method comprising the steps of extracting RNA from blood, plasma, serum, or other bodily fluid, in vitro amplifying in a qualitative or quantitative fashion one or more DNMT mRNA or their cDNA, and detecting the amplified product of DNMT mRNA or its cDNA. Said amplification methods may further include the qualitative or quantitative comparison to a reference RNA species normally present in the blood, plasma, serum, or bodily fluid of individuals with or without cancer.
In a first aspect of this embodiment, the present invention provides methods for detecting DNMT RNA in blood or blood fractions, including circulating cells, plasma and serum, in a human or animal. Said methods are useful for detecting, diagnosing, monitoring, treating and evaluating various proliferative disorders, particularly stages of neoplastic disease, including premalignancy, early cancer, non-invasive cancer, carcinoma in-situ, invasive cancer and advanced cancer. In this aspect, the method comprises the steps of extracting RNA from blood or blood plasma or serum, in vitro amplifying said DNMT RNA comprising the extracted RNA either qualitatively or quantitatively, and detecting the amplified product of DNMT RNA or its cDNA.
The invention in a second aspect provides a method for detecting DNMT RNA in any bodily fluid. Preferably, said bodily fluid is whole blood, blood fractions, blood plasma, serum, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions including sputum, secretions or washings from the breast, or other associated tissue washings or lavages from a human or animal. Additionally, the invention recognizes that DNMT RNA may be assessed from circulating tumor cells derived from blood fractions. In this aspect, the method comprises the steps of extracting RNA from the bodily fluid, in vitro amplifying DNMT RNA comprising a fraction of the extracted RNA, or preferably the corresponding cDNA into which the RNA is converted, in a qualitative or quantitative fashion, and detecting the amplified product of DNMT RNA or cDNA. In these embodiments, the inventive methods are particularly advantageous for detecting, diagnosing, monitoring, treating or evaluating various proliferative disorders, particularly stages of neoplastic disease, including premalignancy, early cancer, non-invasive cancer, carcinoma-in-situ, invasive cancer and advanced cancer.
The method of the invention is additionally useful for identifying DNMT RNA-expressing cells or tissue in an animal, most preferably a human. In these embodiments, detection of an in vitro amplified product of DNMT RNA using the inventive methods indicates the existence of DNMT RNA-expressing cells or tissue in an animal, most preferably a human.
The invention provides primers and probes useful in the efficient amplification of extracellular DNMT mRNA or cDNA from bodily fluid, most preferably blood plasma or serum.
The invention further provides a diagnostic kit for detecting DNMT RNA in bodily fluid, preferably blood plasma or serum, wherein the kit comprises primers, probes or both primers and probes for amplifying and detecting extracellular DNMT RNA or cDNA derived therefrom.
In preferred embodiments of the inventive methods, DNMT RNA is extracted from whole blood, blood plasma or serum, or other bodily fluids using an extraction method such as but not limited to gelatin extraction method; silica, glass bead, or diatom extraction method; guanidinium thiocyanate acid-phenol based extraction methods; guanidinium thiocyanate acid based extraction methods; methods using centrifugation through cesium chloride or similar gradients; phenol-chloroform based extraction methods; or other commercially available RNA extraction methods. Extraction from isolated circulating tumor cells may further be performed using said methods. Extraction may further be performed using probes that specifically hybridize to DNMT RNA.
In preferred embodiments of the inventive methods, DNMT RNA or cDNA derived therefrom is amplified using an amplification method such as reverse transcriptase polymerase chain reaction (RT-PCR); ligase chain reaction; signal amplification such as DNA signal amplification; amplification using amplifiable RNA reporters; Q-beta replication; transcription-based amplification; isothermal nucleic acid sequence based amplification; self-sustained sequence replication assays; boomerang DNA amplification; amplification using strand displacement activation; amplification using cycling probe technology; or any combination or variation thereof.
In preferred embodiments of the inventive methods, detecting an amplification product of DNMT RNA or DNMT cDNA is accomplished using a detection method such as gel electrophoresis; capillary electrophoresis; conventional enzyme-linked immunosorbent assay (ELISA) or modifications thereof, such as amplification using biotinylated or otherwise modified primers; nucleic acid hybridization using specific, detectably-labeled probes, such as fluorescent-, radioisotope-, or chromogenically-labeled probe; Northern blot analysis; Southern blot analysis; electrochemiluminescence; reverse dot blot detection; and high-performance liquid chromatography.
In particularly preferred embodiments of the inventive methods, DNMT RNA is converted to cDNA using reverse transcriptase following extraction of RNA from a bodily fluid and prior to amplification.
The methods of the invention are advantageously used for providing a diagnosis or prognosis of, or as a predictive indicator for determining a risk for an animal, most preferably a human, for developing a proliferative, premalignant, neoplastic or malignant disease comprising or characterized by the existence of cells over expressing DNMT RNA. The methods of the invention are particularly useful for providing a diagnosis for identifying humans at risk for developing or who have developed malignancy or premalignancy and for determining predisposition to malignancy. Identification of said humans enables their selection for treatment approaches directed against DNMT RNA, DNMT DNA or DNMT protein, including treatments directed against hypermethylation or hypomethylation. Most preferably, the malignant or premalignant diseases, conditions or disorders advantageously detected, diagnosed, or inferred using the methods of the invention are breast, prostate, ovarian, lung, cervical, colorectal, gastric, hepatocellular, pancreatic, bladder, endometrial, kidney, skin, brain, head and neck, and esophageal cancers, sarcomas, hematological malignancies including leukemias and lymphomas, and premalignancies and carcinoma in-situ such as prostatic intraepithelial neoplasia (PIN), cervical dysplasia, cervical intraepithelial neoplasia (CIN), bronchial dysplasia, atypical hyperplasia of the breast, ductal carcinoma in-situ, colorectal adenoma, atypical endometrial hyperplasia, myelodysplastic syndromes, and Barrett's esophagus.
In certain preferred embodiments of the methods of the invention, DNMT RNA or cDNA derived therefrom is amplified in a quantitative manner, thereby enabling the quantitative comparison of DNMT RNA present in a bodily fluid such as blood plasma or serum from an animal, most preferably a human. In these embodiments, the amount of extracellular DNMT RNA detected in an individual are compared with a range of amounts of extracellular DNMT RNA detected in said bodily fluid in populations of animals known to have a premalignant, neoplastic, or malignant disease, most preferably a particular premalignant, neoplastic, or malignant disease. Additionally, the amount of extracellular DNMT RNA detected in an individual is compared with a range of amounts of extracellular DNMT RNA detected in said bodily fluid in populations of animals known to be free from a premalignant, neoplastic, or malignant disease. In particularly preferred aspects of this embodiment, comparison of DNMT RNA is further made to a reference RNA extracted, amplified, and detected from said bodily fluid, wherein said reference RNA is not DNMT RNA, but preferably RNA normally present in the bodily fluid of both healthy individuals and those with cancer. In another aspect, said reference RNA is not DNMT RNA, but is RNA present in the bodily fluid of individuals with cancer.
The methods of the invention further provide ways to identify individuals having a DNMT over expressing malignancy or premalignancy, thereby permitting rational, informed treatment options to be used for making therapeutic decisions. In particular, the methods of the invention are useful in identifying individuals having a premalignancy or malignancy that might benefit from a DNA methylation-directed therapy such as anti-methylation agents or antisense agents, either alone or administered with therapeutically-effective amounts of other chemotherapeutic or anticancer drugs. The methods of the invention allow identification of individuals that might benefit from therapeutic approaches that target DNMT mRNA include antisense mRNA directed against DNMT mRNA, and microRNA (miRNA) or other inhibitory RNA (siRNA) therapeutic approaches including synthetic miRNA or siRNA that are directed against DNMT mRNA targets, such as against DNMT3b RNA, and further include drugs that inhibit DNMT DNA function or DNMT protein function. This aspect of the invention is particularly useful in identifying individuals having cancer for said treatments, but further identifying those at risk of malignancy for chemopreventive therapies, whether said therapy is directed at the methylation process or not.
Another advantageous use for the methods of the invention is to provide a marker for assessing the adequacy of anticancer therapy, including synthetic miRNA therapies, antisense RNA based therapies, antiangiogenic therapies, cancer vaccine therapies, monoclonal antibody therapies and other biotherapies, small molecule therapies, surgical intervention, chemotherapy, or radiation therapy, administered preventively or palliatively, or for determining whether additional or more advanced therapy is required. The invention therefore provides methods for developing a prognosis in such patients.
The methods of the invention also allows identification or analysis of DNMT RNA, either qualitatively or quantitatively, in the blood or other bodily fluid of an individual, most preferably a human who has completed therapy, as an early indicator of relapsed cancer, impending relapse, or treatment failure.
Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.
The invention provides methods for detecting DNMT RNA, such as DNMT1 RNA and DNMT3 RNA including DNMT3a RNA and DNMT3b RNA, in bodily fluids of an animal, most preferably a human, thereby enabling detection of cancerous or precancerous cells that overexpress DNMT in the human or animal, and further thereby enabling identification and selection of humans or animals for specific treatment modalities directed against hypermethylation, hypomethylation, of DNMT RNA, DNA, or protein.
In preferred embodiments of the methods of the invention, extracellular RNA containing DNMT RNA is extracted from a bodily fluid. This extracted RNA is then amplified, either after conversion into cDNA or directly, using in vitro amplification methods in either a qualitative or quantitative manner using primers or probes specific for the DNMT RNA or cDNA of interest. The amplified product or signal is then detected in either a qualitative or quantitative manner. Demonstration of overexpression of DNMT RNA thereby identifies or selects an individual for a therapeutic option.
In the practice of the methods of the invention, DNMT RNA may be extracted from any bodily fluid, including but not limited to whole blood, blood fractions including circulating cells and blood plasma, serum, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions including sputum, breast fluid, or secretions or washings or lavages, using, for example, extraction methods described in co-owned U.S. Pat. No. 6,329,179, the entire disclosure of which is hereby been incorporated by reference. In a preferred embodiment, the bodily fluid is either blood, blood plasma or serum. It is preferred, but not required, that blood be processed soon after drawing, and preferably within three hours, as to minimize any nucleic acid degradation in the sample. In a preferred embodiment, blood is first collected by venipuncture and kept on ice until use. Preferably, within 30 minutes to one hour of drawing the blood, serum is separated by a conventional method such as by centrifugation, for example but not limited to 1100×g for 10 minutes at 4° C. When using plasma, the blood is not permitted to coagulate prior to separation of the cellular and acellular components. Serum or plasma can be frozen, most preferably at −70° C. after separation from the cellular portion of blood until further assayed. When using frozen blood plasma or serum, the frozen serum or plasma is rapidly thawed, for example in a 37° C. water bath, and RNA is extracted therefrom without delay, for example using a commercially-available kit (for example, Perfect RNA Total RNA Isolation Kit, obtained from Five Prime—Three Prime, Inc., Boulder, Colo.). Other methods of RNA extraction are further provided in co-owned and co-pending U.S. patent application Ser. No. 09/155,152, incorporated herein by reference in its entirety.
Following the extraction of RNA from a bodily fluid, a fraction of which contains DNMT mRNA, the DNMT mRNA or cDNA derived therefrom is amplified in vitro. Applicable amplification assays are detailed in co-owned U.S. Pat. No. 6,329,179, as herein incorporated by reference, and include but are not limited to reverse transcriptase polymerase chain reaction (RT-PCR), ligase chain reaction, DNA signal amplification methods including branched chain signal amplification, amplification using amplifiable RNA reporters, Q-beta replication, transcription-based amplification, boomerang DNA amplification, amplification using strand displacement activation, amplification using cycling probe technology, isothermal nucleic acid sequence based amplification, and other self-sustained sequence replication assays.
In preferred embodiments of the methods of the invention, DNMT mRNA is converted into cDNA using reverse transcriptase prior to in vitro amplification using methods known in the art. For example, a sample, such as 10 microL extracted serum RNA is reverse-transcribed in a 30 microL volume containing 200 Units of Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega, Madison, Wis.), a reaction buffer supplied by the manufacturer, 1 mM dNTPs, 0.5 micrograms random hexamers, and 25 Units of RNAsin (Promega, Madison, Wis.). Reverse transcription is typically performed under an overlaid mineral oil layer to inhibit evaporation and incubated at room temperature for 10 minutes followed by incubation at 37° C. for one hour.
Alternatively, other methods well known in the art can be used to reverse transcribe DNMT RNA to cDNA, as provided in these references incorporated herein by reference in their entirety, or by oligodT or primer-specific methods of reverse transcription.
Amplification primers are specific for amplifying DNMT-encoding nucleic acid. In a preferred embodiment, amplification of DNMT1, DNMT3a, or DNMT3b is performed by RT-PCR, preferably as set forth in Robertson et al. (Nucleic Acids Res. 27:2291-2298, 1999), incorporated herein by reference in its entirety. In these embodiments, the preferred oligonucleotide primer sequences are as follows:
In one example of a preferred embodiment of the invention, the DNMT RNA of interest is harvested from approximately 1.75 mL aliquots of serum or plasma, and RNA extracted therefrom using the Perfect RNA Total RNA Isolation Kit (Five Prime—Three Prime) or similar commercial extraction kit. From this extracted RNA preparation, 10 microL are then reverse transcribed to cDNA as described above. RT-PCR for the DNMT cDNA of interest is performed using 5 microL of DNMT cDNA in a final volume of 50 microL in a reaction mixture containing 1 U of Amplitaq Gold (Perkin Elmer Corp., Foster City, Calif.), a reaction buffer provided by the Amplitaq supplier, 1.5 mM MgCl2, 200 microM each dNTP, and 10 picomoles each of appropriate primer as identified above (Primer 1 and 2 for DNMT1; Primer 3 and 4 for DNMT3a; Primer 5 and 6 for DNMT3b). The mixture is then amplified in a single-stage reaction in a thermocycler under a temperature profile consisting of an initial 2 minute incubation at 94° C., followed by 45 cycles of denaturation at 94° C. for 30 seconds, annealing at 58° C. for DNMT1 or 65° C. for DNMT3a and DNMT3b, each for 60 seconds, and extension at 72° C. for 60 seconds, followed by a final extension at 72° C. for 5 minutes. Detection of the amplified product is then achieved, for example, by gel electrophoresis through a 4% Tris-borate-EDTA (TBE) agarose gel, using ethidium bromide staining for visualization and identification of the product fragment. Alternatively, the amplified products may thereafter be hybridized to end-labeled oligonucleotide probes and detected, such as using the method of Robertson et al. (Nucleic Acids Res. 27: 2291-2298, 1999). Further, it will be understood that alternative amplification primers and parameters can be utilized using methods known in the art.
The invention provides for alternative methods of amplification of DNMT RNA or cDNA known in the art, including but not limited to the methods of Chen et al. (Int. J. Cancer 83: 10-14, 1999), or Saito et al. (Hepatology 33: 561-568, 2001), incorporated herein by reference in their entirety, and further including signal amplification methods as known in the art. Amplification methods can further be performed in qualitative or quantitative fashion using primers specific for an internal control sequence of a reference RNA, such as glyceraldehyde-3-phosphate dehydrogenase or beta-actin, as described in said references, wherein said controls are RNA present in the bodily fluid of both healthy individuals and individuals with cancer.
In a particularly preferred embodiment, DNMT RNA or cDNA is amplified in a quantitative amplification reaction. Quantitative amplification of DNMT RNA or cDNA is particularly advantageous because this method enables statistically-based discrimination between patients with neoplastic disease and populations without neoplasm, including normal individuals. Using these methods, quantitative distributions of DNMT RNA in bodily fluids such as blood plasma or serum are established in populations with neoplastic diseases, and in normal populations. Using this population information, the amount of extracellular DNMT RNA in an individual is compared with the range of amounts of extracellular DNMT RNA in said populations, wherein a reference range is or has been determined, resulting in a determination of whether the detected amount of extracellular DNMT RNA in an individual indicates that the individual has DNMT RNA overexpression consistent with a premalignant, neoplastic or malignant disease, or has a predisposition to developing such a disease.
In alternative preferred embodiments, amplified products can be detected using other methods, including but not limited to gel electrophoresis; capillary electrophoresis; ELISA or modifications thereof, such as amplification using biotinylated or otherwise modified primers; nucleic acid hybridization using specific, detectably-labeled probes, such as fluorescent-, radioisotope-, or chromogenically-labeled probe; Southern blot analysis; Northern blot analysis; electrochemiluminescence; reverse dot blot detection; and high-performance liquid chromatography. Furthermore, detection may be performed in either a qualitative or quantitative fashion.
PCR product fragments produced using the methods of the invention can be further cloned into recombinant DNA replication vectors using standard techniques. RNA can be produced from cloned PCR products, and in some instances the RNA expressed thereby, using the TnT Quick Coupled Transcription/Translation kit (Promega, Madison, Wis.) as directed by the manufacturer.
The methods of the invention as described above can be performed in like manner for detecting DNMT mRNA from other bodily fluids, including but not limited to whole blood, fractions or components of blood including circulating tumor cells, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, breast fluid or secretions, and bronchial secretions including sputum, and from washings or lavages. Whereas fractionation of the bodily fluid into its cellular and non-cellular components is not required for the practice of the invention, the non-cellular fraction may be separated, for example, by centrifugation or filtration of the bodily fluid.
The methods of the invention are thereby useful in the practice of a diagnostic method for detecting DNMT mRNA or its overexpression in an animal, most preferably a human at risk for developing or who has developed a premalignant, neoplastic or malignant disease consisting of cells over expressing DNMT mRNA. The invention further provides a method of identifying humans at risk for developing, or who have developed premalignancies or cancer, including but not limited to cancers of the breast, prostate, ovary, lung, cervix, colon, rectum, stomach, liver, pancreas, bladder, endometrium, kidney, brain, skin including squamous cell cancer and malignant melanoma, head and neck and esophagus, as well sarcomas and hematological malignancies such as leukemias and lymphomas, and further premalignancies and carcinoma in-situ including but not limited to prostatic intraepithelial neoplasia (PIN), cervical dysplasia and cervical intraepithelial neoplasia (CIN), bronchial dysplasia, atypical hyperplasia of the breast, ductal carcinoma in-situ, colorectal adenoma, atypical endometrial hyperplasia, myelodysplastic syndromes and Barrett's esophagus.
The diagnostic methods and advantageous applications of the invention can be performed using a diagnostic kit as provided by the invention, wherein the kit includes primers specific for DNMT cDNA synthesis or in vitro amplification or both, and/or specific probes for detecting DNMT RNA species, cDNA or in vitro amplified DNA fragments or amplified signals thereof. The kit may further include methods and reagents for extracting DNMT RNA from an extracellular bodily fluid, wherein the bodily fluid includes but is not limited to plasma or serum.
The inventive methods have significant utility in identifying individuals as a candidate who are might most benefit from therapies, and assigning and monitoring therapies, including anti-neoplastic therapies such as chemotherapy, biotherapies including cancer vaccine and monoclonal antibody therapies, antiangiogenic therapies, radiation, and surgery, and therapies such as antisense therapies, synthetic miRNA-based therapies and methylation-directed therapeutic agents. Synthetic miRNA therapies can include, but not be limited to synthetic miR-148 to target human DNMT3b, and synthetic miRNA-29b to target DNMT3a and DNMT3b. The inventive methods are also useful for monitoring response, relapse, and prognosis of DNMT producing neoplastic diseases. Of particular value, the invention allows a determination that a therapy is therapeutically indicated even in cases of premalignancy, early cancer, occult cancer or minimum residual disease are present. Thus, the invention permits selection of patients for said therapies or monitoring of therapeutic intervention, including chemoprevention, when tumor burden is low or when malignancy has not yet developed.
The invention further enables DNMT RNA to be evaluated in blood plasma or serum or other bodily fluid in combination with detection of other tumor-associated or tumor-derived RNA or DNA, including hypermethylated or aberrantly methylated DNA, in a concurrent or sequential fashion, such as in a multiplexed assay or in a chip-based assay, thereby increasing the sensitivity or efficacy of the assay in the detection or monitoring of neoplastic diseases, or in monitoring and evaluating aberrant DNA methylation processes.
The methods of the invention and preferred uses for the methods of the invention are more fully illustrated in the following Example. This Example illustrates certain aspects of the above-described method and advantageous results. This Example is shown by way of illustration and not by way of limitation.
A 37 year old man with a family history of colorectal cancer undergoes a cancer predisposition screening test by providing a blood plasma sample for a multiplexed assay that includes evaluation of the plasma for DNMT RNA. DNMT RNA is evaluated by the methods of the invention in a quantitative manner as described. In addition, other tumor-associated nucleic acids, including K-ras DNA and hTERT RNA, are evaluated by the multiplexed assay. The assay indicates DNMT RNA is present in the plasma at levels higher than expected in the normal population. In addition, the multiplexed assay is positive for mutated K-ras oncogene present in the plasma, but negative for hTERT RNA. Overall, the assay results would indicate an increased predisposition for neoplasia. The man would subsequently undergo a conventional colonoscopy, and have two adenoma detected and removed. As the patient is considered at high risk for developing colorectal neoplasia in the future, the man would start a chemopreventive drug therapy regimen. Serial evaluation of quantitative DNMT RNA levels in plasma is undertaken to evaluate response to the chemoprevention regimen. DNMT RNA levels demonstrate progressive decline into the range for a normal population during the treatment period, indicating a good response to therapy.
This example demonstrates use of the invention for detection and monitoring of neoplasia, and determining predisposition to neoplasia. Furthermore, the example demonstrates use of the invention in monitoring response to a chemoprevention regimen.
A 43 year old woman with metastatic breast cancer has a peripheral blood specimen drawn. RNA is extracted either from the whole blood specimen, or from isolated circulating tumor cells, or from extracellular RNA in the blood plasma. The RNA is then reverse transcribed to cDNA and amplified by RT-PCR using primers specific to DNMT3b cDNA. Amplification is performed in a quantitative manner with the quantitative values of the amplified product compared to a reference range of concentrations of DNMT3b amplified product from healthy individuals. It is determined thereby that the amount or concentration of DNMT3b RNA in the woman is greater than that for a normal reference population, and thereby demonstrated that the woman overexpresses DNMT3b RNA, and is thereby identified as a candidate for therapy directed against DNMT3b. The woman is thereupon started on a therapy, for example using synthetic miRNA-29b, and response to therapy is monitored in a serial manner using the methods of the invention.
| Number | Date | Country | |
|---|---|---|---|
| 60332622 | Nov 2001 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10288935 | Nov 2002 | US |
| Child | 12062879 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12062879 | Apr 2008 | US |
| Child | 12617047 | US |
